Intermediate-dose cidofovir without probenecid in the treatment of BK virus allograft nephropathy.

@article{Araya2006IntermediatedoseCW,
  title={Intermediate-dose cidofovir without probenecid in the treatment of BK virus allograft nephropathy.},
  author={Carlos Enrique Araya and Judy F. Lew and Robert S. Fennell and Richard E. Neiberger and Vikas R Dharnidharka},
  journal={Pediatric transplantation},
  year={2006},
  volume={10 1},
  pages={
          32-7
        }
}
BK virus allograft nephropathy (BKVAN) is a rising complication in kidney transplant recipients. Reducing immunosuppression has been the initial form of therapy in most cases, but is not always associated with improvement in graft function. Anti-viral therapy with low-dose cidofovir (0.25-0.42 mg/kg/dose) has been used successfully in some patients, but dose-related nephrotoxicity has limited its use. We present our experience with 3 kidney transplant recipients diagnosed with BKVAN who… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

Treatment of polyomavirus infection in kidney transplant recipients: a systematic review.

  • Transplantation
  • 2010
VIEW 6 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Intravenous immunoglobulin as rescue therapy for BK virus nephropathy.

  • Pediatric transplantation
  • 2009
VIEW 5 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Use of cidofovir in recurrent respiratory papillomatosis

  • European Archives of Oto-Rhino-Laryngology
  • 2013

Similar Papers

Loading similar papers…